Danaher Corp (NY:DHR)

232.00 -0.97 (-0.42%)

Official Closing Price Updated: 7:00 PM EDT, Oct 27, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Danaher Corp

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

30 31 Next >

Unpacking the Latest Options Trading Trends in Danaher ↗

April 04, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

March 28, 2024

Via Benzinga

Danaher Options Trading: A Deep Dive into Market Sentiment ↗

March 27, 2024

Via Benzinga

Invest Like Bill Gates With These 3 AI Stocks to Buy ↗

March 27, 2024

Bill Gates is undoubtedly interested in AI stocks to buy. Here are three of his foundation’s current holdings.

Via InvestorPlace

Topics Artificial Intelligence

Looking Into Danaher's Recent Short Interest ↗

March 26, 2024

Via Benzinga

If You Invested $100 In This Stock 10 Years Ago, You Would Have $500 Today ↗

March 25, 2024

Via Benzinga

Danaher's Options Frenzy: What You Need to Know ↗

March 15, 2024

Via Benzinga

Here's How Much $1000 Invested In Danaher 5 Years Ago Would Be Worth Today ↗

March 15, 2024

Via Benzinga

$1000 Invested In Danaher 10 Years Ago Would Be Worth This Much Today ↗

February 28, 2024

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

March 20, 2024

Via Benzinga

Top 7 Biotech Winners Of Novo Nordisk, Eli Lilly's Outsourcing Strategy For Weight-Loss Drugs: Goldman Sachs ↗

March 13, 2024

Goldman Sachs analysts identified a substantial opportunity in the manufacturing sector for new obesity therapeutics, as demand for these treatments escalates.

Via Benzinga

Danaher's Spun-Off Company Veralto Is "Next High-Quality Serial Compounder" - Analyst ↗

February 27, 2024

Analyst initiates coverage on Veralto Corporation at Outperform rating with $97 price target. Sees strong EPS growth, high-margin businesses, and M&A potential.

Via Benzinga

Beyond Tech And AI: Why The Sector Hedge Funds Prefer Is Not The One You'd Expect ↗

February 27, 2024

Hedge funds are shifting towards stability and value by favoring the health care sector over booming tech stocks.

Via Benzinga

Unpacking the Latest Options Trading Trends in Danaher ↗

February 22, 2024

Via Benzinga

Behind the Scenes of Danaher's Latest Options Trends ↗

February 14, 2024

Via Benzinga

Here's How Much You Would Have Made Owning Danaher Stock In The Last 10 Years ↗

February 06, 2024

Via Benzinga

DANAHER ALERT: Bragar Eagel & Squire, P.C. is Investigating Danaher Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

February 25, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

AT&T To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Thursday ↗

February 01, 2024

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Danaher Analysts Increase Their Forecasts After Upbeat Earnings ↗

January 31, 2024

Danaher Corporation (NYSE: DHR) posted better-than-expected fourth-quarter financial results on Tuesday.

Via Benzinga

US Stocks Ease Ahead Of Key Tech Earnings, UPS Sinks, General Motors Rallies: What's Driving Markets Tuesday? ↗

January 30, 2024

Traders cautious ahead of tech earnings & FOMC meeting. S&P 500 & Nasdaq 100 down, Dow slightly up. Dollar & Treasury steady. JOLTS & home price data positive. UPS falls 7%, GM up 8%, Danaher up 3.5%,...

Via Benzinga

Topics Stocks

Earnings Outlook For Danaher ↗

January 29, 2024

Via Benzinga

A Glimpse Into The Expert Outlook On Danaher Through 4 Analysts ↗

January 24, 2024

Via Benzinga

Life Science Giant Danaher Warns Of Sales Decline In 2024; Says 'Pandemic Has Transitioned To An Endemic State' ↗

January 30, 2024

Danaher reported Q4 2023 adjusted EPS of $2.09, exceeding consensus of $1.89. Sales decreased 10% Y/Y to $6.4B. Non-GAAP core revenue declined 11.5%. Guidance for core revenue growth will continue, but...

Via Benzinga

Earnings Scheduled For January 30, 2024 ↗

January 30, 2024

Companies Reporting Before The Bell • CommVault Systems (NASDAQ:CVLT) is estimated to report quarterly earnings at $0.73 per share on revenue of $208.06 million.

Via Benzinga

$1000 Invested In Danaher 10 Years Ago Would Be Worth This Much Today ↗

January 19, 2024

Via Benzinga

DANAHER ALERT: Bragar Eagel & Squire, P.C. is Investigating Danaher Corporation on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

January 29, 2024

From Bragar Eagel & Squire

Via GlobeNewswire

Stocks Ease Despite Benign Inflation Data, Bitcoin Stages Comeback: What's Driving Markets Friday? ↗

January 26, 2024

Stocks mixed in New York, with investors assessing mild inflation report and strong personal spending figures. Short-term Treasury yields rise, tech stocks lag, and Bitcoin surges 4.9%. Intel stock...

Via Benzinga

Topics Economy

Jim Cramer: Stay Away From This Major Airline Stock, 'People Should Understand Airlines Are Trades' ↗

January 24, 2024

On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended to stay away from Delta Air Lines, Inc. (NYSE: DAL). "People should understand airlines are trades," he noted.

Via Benzinga

How Good Is Your Market Cap Knowledge? ↗

January 11, 2024

A company with a $50 price per share might have a million shares outstanding or a billion shares outstanding. And unless you know, you don't know the price tag of the stock you're about to buy.

Via The Motley Fool

Will Danaher stock hit new highs in 2024?

January 10, 2024

Danaher raises guidance, sending shares higher, but the move may not last. Resistance is just above current levels and may cap gains until later in the year.

Via MarketBeat

Topics Artificial Intelligence

< Previous 1 2

...

11 12 13 14 15 16 17 18 19

...

30 31 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.